|View printer-friendly version|
– SER-155, a preclinical stage, synthetic microbiome therapeutic candidate, is being developed to prevent serious bacterial infections and graft versus host disease in patients following solid organ and allogeneic stem cell transplantation –
SER-155 is a synthetic, rationally-designed microbiome therapeutic candidate designed to prevent antibiotic-resistant bacterial infections and graft versus host disease in patients following solid organ and allogeneic stem cell transplantation. A significant contribution to the mortality associated with allogeneic stem cell transplantation is the result of bacterial infection and graft versus host disease.1 The SER-155 program will leverage Seres’ advanced microbiome manufacturing capabilities. Seres is the first microbiome company to have brought a synthetic, rationally-designed microbiome development candidate into the clinic with SER-262, an investigational therapeutic, currently being evaluated in a Phase 1b trial.
“We are delighted to have obtained the support of CARB-X, which is a
further testament to the potential of microbiome therapeutics in diverse
areas of medicine. The spread of drug-resistant bacterial infections is
an urgent public health concern and new approaches are desperately
needed. Published clinical data by our collaborators, Dr.
SER-155 is a preclinical stage Ecobiotic® rationally designed microbiome therapeutic candidate. The development of SER-155 is supported by clinical data, including data published by Seres’ collaborators at
About Seres Therapeutics
CARB-X is the world’s largest public-private partnership devoted to antibacterial preclinical R&D. Funded by
1) Taur et al,.
2) Jenq R et al., Intestinal Blautia Is associated with reduced death from graft-versus-host disease. Biology of Blood and Marrow Transplantation, 2015.
3) Taur Y et al., The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation. Blood, 2014.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the receipt of milestone payments, dysbiosis as an underlying cause of disease, the impact Seres’ manufacturing capabilities may have on SER-155, and the potential clinical development and effectiveness of SER-155.
These forward-looking statements are based on management’s current
expectations. These statements are neither promises nor guarantees, but
involve known and unknown risks, uncertainties and other important
factors that may cause our actual results, performance or achievements
to be materially different from any future results, performance or
achievements expressed or implied by the forward-looking statements,
including, but not limited to, the following: we have incurred
significant losses, are not currently profitable and may never become
profitable; our need for additional funding; our limited operating
history; our unproven approach to therapeutic intervention; the lengthy,
expensive, and uncertain process of clinical drug development, including
potential delays in regulatory approval; our reliance on third parties
and collaborators to conduct our clinical trials, manufacture our
product candidates, and develop and commercialize our product
candidates, if approved; our lack of experience in manufacturing,
selling, marketing, and distributing our product candidates; failure to
compete successfully against other drug companies; protection of our
proprietary technology and the confidentiality of our trade secrets;
potential lawsuits for, or claims of, infringement of third-party
intellectual property or challenges to the ownership of our intellectual
property; our patents being found invalid or unenforceable; risks
associated with international operations; our ability to retain key
personnel and to manage our growth; the potential volatility of our
common stock; our management and principal stockholders have the ability
to control or significantly influence our business; and we are currently
subject to securities class action litigation. These and other important
factors discussed under the caption “Risk Factors” in our Quarterly
Report on Form 10-Q filed with the
IR or PR Contact:
Carlo Tanzi, Ph.D., 617-203-3467
Head of Investor Relations and Corporate Communications